Floatz Rating
B61/100
Confidence
Indicative
Sponsor
Fred Hutchinson Cancer Center
Modality
protein_peptide
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
46High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01527045CT.gov Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies | — | Completed | — | — | — |
NCT00796068CT.gov Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Bone Marrow Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cyclosporin A (this asset) | Fred Hutchinson Cancer Center | P2 | B · 61 |
| Fludarabine | Fred Hutchinson Cancer Center | P2 | BB |
| Vancomycin | European Organisation for Research and Treatment of Cancer - EORTC | P3 | BB |
| Piperacillin | European Organisation for Research and Treatment of Cancer - EORTC | P3 | BB |
| Tazobactam | European Organisation for Research and Treatment of Cancer - EORTC | P3 | BB |
| Nivestim | Fred Hutchinson Cancer Center | P2 | B |
| Treosulfan | Fred Hutchinson Cancer Center | P2 | B |
| Atorvastatin | Fred Hutchinson Cancer Center | P2 | B |
| Pelabresib | Constellation Pharmaceuticals | P1/2 | CCC |
+18 more in the Bone Marrow Disorder cohort
Other indications for Cyclosporin A
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Hodgkin Lymphoma | — | P3 | BBB · 76 |
| Myelodysplastic/Myeloproliferative Neoplasm | — | P3 | BBB · 76 |
| Disease Related To Transplantation | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- FludarabineFred Hutchinson Cancer CenterBB
- VancomycinEuropean Organisation for Research and Treatment of Cancer - EORTCBB
- PiperacillinEuropean Organisation for Research and Treatment of Cancer - EORTCBB
- TazobactamEuropean Organisation for Research and Treatment of Cancer - EORTCBB
- NivestimFred Hutchinson Cancer CenterB
Citation
Floatz Terminal. Cyclosporin A in Bone Marrow Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cyclosporin-a-bone-marrow-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →